KPRX Kiora Pharma: ערך חשבונאי למניה

Kiora Pharmaceuticals (KPRX) minimizes regulatory risks through a multi-stage portfolio of therapies for rare retinal pathologies. The current book value per share reflects asset dynamics, with the value settling at 3.79. A narrow development profile ensures stable demand, while stringent FDA standards and patent protection for small molecules create a robust barrier to entry for new players.

Book value per share is calculated as the ratio of equity minus all liabilities to the number of outstanding shares, reflecting the actual value of net assets. For Kiora Pharmaceuticals (KPRX), this metric is critical, as intensive expenditures on small molecule clinical trials reduce capital, making the historical book value per share chart the primary indicator of financial resilience against development failure risks.